Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
149.13
+6.60 (4.63%)
At close: Dec 16, 2025, 4:00 PM EST
149.13
0.00 (0.00%)
After-hours: Dec 16, 2025, 4:00 PM EST
Belite Bio Employees
Belite Bio had 25 employees as of December 31, 2024. The number of employees increased by 5 or 25.00% compared to the previous year.
Employees
25
Change (1Y)
5
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,495,480
Market Cap
5.56B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BLTE News
- 14 days ago - Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
- 14 days ago - Why Belite Bio Stock Soared on Monday - The Motley Fool
- 15 days ago - Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
- 15 days ago - Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript - Seeking Alpha
- 15 days ago - Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease - Benzinga
- 15 days ago - Belite Bio's drug for genetic eye disease meets main goal in late-stage trial - Reuters
- 15 days ago - New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript - Seeking Alpha